Table 3.
Experiment | Treatment onset | Dose level (mg/kg) | Weight loss (g) | Mortality |
---|---|---|---|---|
Dose response | 24 h preischemic | Vehicle | 5.3 ± 0.5 | 0/6 |
100 | 4.3 ± 0.6 | 0/6 | ||
200 | 3.5 ± 0.4 | 1/8 | ||
300 | 4.5 ± 0.5 | 2/9 | ||
Therapeutic window | 1–6 h postischemic | Vehicle | 4.9 ± 0.3 | 1/30 |
1 h postischemic | 200 | 5.7 ± 0.2 | 1/9 | |
3 h postischemic | 200 | 5.2 ± 0.2 | 0/15 | |
6 h postischemic | 200 | 5.6 ± 0.3 | 1/8 | |
Female | 1 h postischemic | Vehicle | 2.9 ± 0.5 | 0/9 |
200 | 3.5 ± 0.4 | 0/9 | ||
Aged (12 months) | 1 h postischemic | Vehicle | 4.2 ± 0.7 | 1/7 |
200 | 3.4 ± 0.6 | 2/8 | ||
Diabetic (db/db) | 1 h postischemic | Vehicle | 3.8 ± 0.3 | 0/6 |
200 | 3.8 ± 0.3 | 0/8 | ||
Atorvastatin (20 mg/kg) | 1 h postischemic | Vehicle | 3.3 ± 0.8 | 1/7 |
200 | 5.7 ± 0.3* | 1/7 | ||
Permanent ischemia | 1 h postischemic | Vehicle | 4.0 ± 0.3 | 2/12 |
200 | 3.5 ± 0.3 | 6/15 |
All treatments were administered every 12 h via oral gavage until sacrifice at 48 h (24 h in permanent ischemia experiment). Please see and for details of experimental groups and protocols, and the treatment paradigms. Weight loss expressed as mean ± SEM.
P < 0.05 versus atorvastatin plus vehicle. Unpaired t-test or one-way ANOVA for weight loss, chi-square or Fisher’s exact test for mortality.